YolTech Therapeutics is a clinical-stage biotechnology company focused on developing next-generation in vivo gene-editing therapies for one-time treatment. Founded in 2021, the company has established a comprehensive platform featuring proprietary CRISPR nucleases, base editors, and a lipid nanoparticle delivery system to enable precise and efficient gene editing. YolTech's clinical pipeline includes programs targeting transthyretin amyloidosis, familial hypercholesterolemia, primary hyperoxaluria type 1, and β-thalassemia/sickle cell disease. The company operates a cGMP-compliant manufacturing facility to support clinical supply and early commercial scale-up.